Loading data for REVB — first visit, this takes a few seconds.
Revelation Biosciences, Inc.
0.99 -0.01 (-1.00%)
0.99 +0.00%
- Рыночная капитализация
- $3.95M
- Объём торгов
- 3.44K
- Следующая дата отчётности
- Nov 5, 2026
Revelation Biosciences, Inc. (REVB): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $0 | n/a | n/a |
| EPS | -$0.87 | -$0.04 | +96.90% |
Метрики
- Бид
- 0.68
- Рыночная капитализация
- 3.95M
- Выручка (TTM)
- n/a
- Чистая прибыль (TTM)
- -19.2M
- -0.14
- 27.03
- 0.04
- -0.34
- P/B (TTM)
- 0.39
- P/S (TTM)
- n/a
- Дата отчёта
- Nov 5, 2026
- Аск
- 1.29
- Объём торгов
- 3,445
- Ср. объём (20д)
- 41,020
- Открытие
- 1.00
- Пред. закрытие
- 1.00
- Диапазон дня
- 0.99 - 1.00
- Диапазон за 52 недели
- 0.88 - 7.60
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании Revelation Biosciences, Inc.
Профиль →Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Отрасль Biotechnology
Сектор Healthcare
Дата IPO Nov 17, 2020
Сотрудники 8
Биржа NasdaqCM
Тикер REVB